Quarterly report pursuant to Section 13 or 15(d)

Revenues from Contracts and Significant Customers (Tables)

v3.22.2.2
Revenues from Contracts and Significant Customers (Tables)
9 Months Ended
Sep. 30, 2022
Revenues from Contracts and Significant Customers  
Schedule of disaggregation of total revenues

Three months ended September 30, 

Nine Months Ended September 30, 

    

2022

    

2021

    

2022

    

2021

Revenue

Qbrexza®

$

6,265

$

6,636

$

19,752

$

11,204

Accutane®

4,121

3,531

14,228

5,672

Amzeeq®

1,161

5,892

Targadox®

1,168

5,184

6,558

18,110

Ximino®

1,773

2,864

3,775

6,277

Zilxi®

554

1,851

Exelderm®

1,001

1,366

3,018

4,319

Other branded revenue

29

35

Collaboration revenue

364

1,446

1,518

4,646

Revenue – related party

 

48

 

29

 

118

 

252

Other revenue

73

2,629

 

Net revenue

$

16,528

$

21,085

$

59,339

$

50,515